Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 1 of 1 for:    NCT03501381
Previous Study | Return to List | Next Study

High Dose IL 2 and Entinostat in RCC

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03501381
Recruitment Status : Recruiting
First Posted : April 18, 2018
Last Update Posted : November 27, 2019
Indiana University Melvin and Bren Simon Cancer Center
Prometheus Laboratories
Syndax Pharmaceuticals
Information provided by (Responsible Party):
Roberto Pili, Hoosier Cancer Research Network

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2023